Source comparison
How to Use CJC-1295 for Growth Hormone Release Protocol: Peptide Comparison
CJC-1295's extended half-life distinguishes it from other GHRH analogues and growth hormone secretagogues. The table below compares CJC-1295 with DAC to structurally similar peptides and alternative GH-boosting compounds. CJC-1295 with DAC GHRH receptor agonis
This comparison does not assign a generated winner or score.
- CJC-1295's extended half-life distinguishes it from other GHRH analogues and growth hormone secretagogues. The table below compares CJC-1295 with DAC to structurally similar peptides and alternative GH-boosting compounds.
- CJC-1295 with DAC
- GHRH receptor agonist with albumin-binding moiety
- 6–8 days
- 1–2× weekly
- 200–300% increase
- Best for sustained weekly protocols; minimal injection burden; synergises with GHRPs for 3–5× GH output
- CJC-1295 without DAC (Mod GRF 1-29)
- GHRH receptor agonist, no DAC
- ~30 minutes
- 2–3× daily
- 150–200% increase per pulse
- Requires multiple daily injections; shorter pharmacokinetic profile suits pulsatile studies
- Ipamorelin
- Ghrelin receptor agonist (GHRP)
- ~2 hours
- 100–150% increase per pulse
- Highly selective ghrelin mimetic; minimal cortisol/prolactin elevation; ideal for CJC-1295 combination
- GHRP-2
- ~20 minutes
- 200–250% increase per pulse
- Stronger GH pulse than Ipamorelin but elevates cortisol and prolactin; less selective
- MK 677 (Ibutamoren)
- Oral ghrelin mimetic
- 24 hours
- Once daily (oral)
- 50–100% sustained increase
- Oral convenience; sustained but lower GH elevation; appetite stimulation side effect common